Logo

Bio-Thera Signs a License Agreement with Intract for Soteria and Phloral Technologies to Develop Oral Antibody Therapies

Share this

Bio-Thera Signs a License Agreement with Intract for Soteria and Phloral Technologies to Develop Oral Antibody Therapies

Shots:

  • Intract to receive an up front- development & commercial milestone along with royalties on product sales. Bio-Thera gets global license to Intract’s Soteria & Phloral oral drug delivery platform to develop a mAb product for chronic GI inflammatory diseases
  • Intract will be responsible for preclinical research of the product while Bio-Thera will get an option to expand the development of the product for multiple GI indications & will lead the manufacturing & commercialization of any approved products
  • Intract’s Soteria protects proteins such as mAbs from degradation in intestinal lumen whereas Phloral utilizes pH & enzymes produced by colonic bacteria to allow payloads in the colon

  | Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions